Andersen J - Search Results

1

Does cellular iron dysregulation play a causative role in Parkinson's disease?

Kaur D, Andersen J. Kaur D, et al. Among authors: andersen j. Ageing Res Rev. 2004 Jul;3(3):327-43. doi: 10.1016/j.arr.2004.01.003. Ageing Res Rev. 2004. PMID: 15231240 Review.

2

What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease?

Andersen JK. Andersen JK. Mech Ageing Dev. 2000 Sep 1;118(1-2):15-22. doi: 10.1016/s0047-6374(00)00150-0. Mech Ageing Dev. 2000. PMID: 10989121 Review.

3

Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?

Andersen JK. Andersen JK. Novartis Found Symp. 2001;235:11-20; discussion 20-5. Novartis Found Symp. 2001. PMID: 11280021 Review.

4

Does neuronal loss in Parkinson's disease involve programmed cell death?

Andersen JK. Andersen JK. Bioessays. 2001 Jul;23(7):640-6. doi: 10.1002/bies.1089. Bioessays. 2001. PMID: 11462217 Review.

5

Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease?

Rajagopalan S, Andersen JK. Rajagopalan S, et al. Among authors: andersen jk. Mech Ageing Dev. 2001 Sep 30;122(14):1499-510. doi: 10.1016/s0047-6374(01)00283-4. Mech Ageing Dev. 2001. PMID: 11511392 Review.

6

Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK. Viswanath V, et al. Among authors: andersen jk. J Neurosci. 2001 Dec 15;21(24):9519-28. doi: 10.1523/JNEUROSCI.21-24-09519.2001. J Neurosci. 2001. PMID: 11739563 Free PMC article.

7

Glutathione, iron and Parkinson's disease.

Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Bharath S, et al. Biochem Pharmacol. 2002 Sep;64(5-6):1037-48. doi: 10.1016/s0006-2952(02)01174-7. Biochem Pharmacol. 2002. PMID: 12213603 Review.

8

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Kaur D, et al. Among authors: andersen jk. Neuron. 2003 Mar 27;37(6):899-909. doi: 10.1016/s0896-6273(03)00126-0. Neuron. 2003. PMID: 12670420 Free article.

9

The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease.

Peng J, Andersen JK. Peng J, et al. Among authors: andersen jk. IUBMB Life. 2003 Apr-May;55(4-5):267-71. doi: 10.1080/1521654031000121666. IUBMB Life. 2003. PMID: 12880208 Free article. Review.

10

Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?

Kaur D, Andersen JK. Kaur D, et al. Aging Cell. 2002 Oct;1(1):17-21. doi: 10.1046/j.1474-9728.2002.00001.x. Aging Cell. 2002. PMID: 12882349 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,221 results

Search Page